- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01447511
Pharmacogenetics of Warfarin Induction and Inhibition
This research study will help determine how a person's genetic makeup affects their response to drugs, the ability of the body to break down drugs, and their potential to experience an interaction between drugs. The investigators are investigating the drug interactions with the commonly used anticoagulant drug called warfarin. Warfarin is used for the treatment and prevention of life-threatening abnormal blood clots such as deep vein thrombosis, heart attacks, and strokes. The investigators chose warfarin for this study because it is a commonly used drug and must be monitored closely to avoid side effects. The investigators are interested in studying whether individuals with certain genetic profiles react differently to warfarin when it is combined with other drugs. This research is being done to see if certain genetic profiles require us to adjust warfarin doses differently than is needed for the general population. Genetic profiles of subjects are determined from their participation in the Pharmacogenetics Registry study (investigator Richard Brundage, University of Minnesota).
The study hypothesis is: Functionally defective CYP2C9 alleles attenuate the warfarin-fluconazole inhibitory interaction and exacerbate the warfarin-rifampin inductive interaction.
Przegląd badań
Status
Warunki
Interwencja / Leczenie
Szczegółowy opis
The research question is: How does CYP2C9 genotype modify warfarin drug interactions?
People differ in their genetic makeup. This includes differences in genes involved in drug metabolism, transport, and effect in the body. People with certain genetic profiles produce altered enzymes, transporters, and receptors that may respond in different ways to drugs. Altered enzymes cause some drugs to be broken down at a different rate than normal. As a result, drug concentrations build up in the blood, and increase the risk of side effects. Furthermore, when two drugs are taken together, the possibility exists for the drugs to interact, with one drug causing a change in the metabolism of the other or both of the drugs. It is not known whether people with an altered genetic makeup also have an altered experience with drug interactions. Altered drug transporters can affect the absorption and elimination of drugs as compared to normal causing differences in how long the drug stays in the body. Finally, altered drug receptors can respond differently to drugs and, thus, produce altered desired or undesired effects.
In this study, the investigators will be investigating the drug interactions with the commonly used anticoagulant drug warfarin in subjects with five different CYP2C9 genotypes. The CYP2C9 genotype is particularly important because this drug metabolizing enzyme governs the metabolic clearance of the more potent chemical entity (the S-enantiomer) of the drug. Warfarin is used for the treatment and prevention of life-threatening abnormal blood clots such as deep vein thrombosis, myocardial infarction, and strokes. The investigators chose warfarin for this study because it is a commonly used drug and must be monitored closely to avoid side effects. The investigators are interested in studying whether individuals with certain genetic alleles of the CYP2C9 genotype react differently to warfarin when it is combined with an antifungal (fluconazole) that inhibits CYP2C9-mediated metabolism and an antibiotic (rifampin) that induces CYP2C9-mediated metabolism. This research is being done to see if certain genetic profiles require us to adjust warfarin doses differently than is needed for the general population.
The study hypothesis is: Functionally defective CYP2C9 alleles attenuate the warfarin-fluconazole inhibitory interaction and exacerbate the warfarin-rifampin inductive interaction.
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Minnesota
-
Minneapolis, Minnesota, Stany Zjednoczone, 55414
- Clinical and Translational Science Institute
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Subjects will be 18-60 years old.
- Women of child bearing age must be willing to use measures to avoid conception during the study period.
- Subjects must agree not to take any known substrates, inhibitors, inducers or activators of either CYP2C9 or CYP3A4 from 1 week prior to the start of each study through the last day of study.
Exclusion Criteria:
- Current cigarette smoker
- Abnormal renal, liver function tests, physical exam, or recent history of hepatic, renal, gastrointestinal or neoplastic disease.
- Allergy to warfarin, fluconazole or rifampin and other chemically related drugs.
- Recent ingestion (< 1 week) of any medication known to be metabolized by or alter CYP2C9 or CYP3A4 activity.
- A positive pregnancy test at the time of the pharmacokinetic study.
- Lab tests indicative of abnormal blood clotting capacity.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Podstawowa nauka
- Przydział: Nielosowe
- Model interwencyjny: Przydział równoległy
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Inny: CYP2C9*1/*1 Genotype
This genotype is considered the wild type genotype.
Individuals with the CYP2C9*1/*1 genotype have two *1 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
|
A single 10 mg warfarin dose taken at the start of the study period.
No other medications taken during this study period.
Inne nazwy:
A single 10 mg warfarin dose taken at the start of the study period.
400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Inne nazwy:
A single 10 mg warfarin dose taken at the start of the study period.
300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Inne nazwy:
|
Inny: CYP2C9*1B/*1B Haplotype
Individuals with the CYP2C9*1B/*1B haplotype have two CYP2C9*1B alleles and participated in the following interventions: Control - Warfarin only and Rifampin - Warfarin.
|
A single 10 mg warfarin dose taken at the start of the study period.
No other medications taken during this study period.
Inne nazwy:
A single 10 mg warfarin dose taken at the start of the study period.
300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Inne nazwy:
|
Inny: CYP2C9*1/*3 Genotype
Individuals with the CYP2C9*1/*3 genotype have one *1 allele and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
|
A single 10 mg warfarin dose taken at the start of the study period.
No other medications taken during this study period.
Inne nazwy:
A single 10 mg warfarin dose taken at the start of the study period.
400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Inne nazwy:
A single 10 mg warfarin dose taken at the start of the study period.
300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Inne nazwy:
|
Inny: CYP2C9*2/*3 Genotype
Individuals with the CYP2C9*2/*3 genotype have one *2 and one *3 allele and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
|
A single 10 mg warfarin dose taken at the start of the study period.
No other medications taken during this study period.
Inne nazwy:
A single 10 mg warfarin dose taken at the start of the study period.
400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Inne nazwy:
A single 10 mg warfarin dose taken at the start of the study period.
300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Inne nazwy:
|
Inny: CYP2C9*3/*3 Genotype
Individuals with the CYP2C9*3/*3 genotype have two *3 alleles and participated in the following interventions: Control - Warfarin only, Fluconazole - Warfarin, and Rifampin - Warfarin.
|
A single 10 mg warfarin dose taken at the start of the study period.
No other medications taken during this study period.
Inne nazwy:
A single 10 mg warfarin dose taken at the start of the study period.
400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
Inne nazwy:
A single 10 mg warfarin dose taken at the start of the study period.
300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
Inne nazwy:
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Warfarin Clearance.
Ramy czasowe: Over three (two for CYP2C9*1B/*1B participants) 12-16 day study periods.
|
Warfarin enantiomer (S-warfarin and R-warfarin) clearance was measured in healthy volunteers genotyped for CYP2C9*1/*1, CYP2C9*1B/*1B, CYP2C9*1/*3, CYP2C9*2/*3 and CYP2C9*3/*3 to determine the magnitude of the warfarin-fluconazole (inhibition) and warfarin-rifampin (induction) drug interactions.
|
Over three (two for CYP2C9*1B/*1B participants) 12-16 day study periods.
|
Współpracownicy i badacze
Sponsor
Współpracownicy
Śledczy
- Główny śledczy: Richard Brundage, PhD, University of Minnesota
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Fizjologiczne skutki leków
- Molekularne mechanizmy działania farmakologicznego
- Środki przeciwinfekcyjne
- Inhibitory syntezy kwasów nukleinowych
- Inhibitory enzymów
- Hormony, substytuty hormonów i antagoniści hormonów
- Środki przeciwbakteryjne
- Inhibitory enzymów cytochromu P-450
- Leprostatycy
- Antagoniści hormonów
- Induktory enzymów cytochromu P-450
- Środki przeciwgrzybicze
- Antykoagulanty
- Inhibitory syntezy sterydów
- Induktory cytochromu P-450 CYP3A
- Środki przeciwgruźlicze
- Inhibitory 14-alfa demetylazy
- Antybiotyki, Przeciwgruźlicze
- Induktory cytochromu P-450 CYP2B6
- Induktory cytochromu P-450 CYP2C8
- Induktory cytochromu P-450 CYP2C19
- Induktory cytochromu P-450 CYP2C9
- Inhibitory cytochromu P-450 CYP2C9
- Inhibitory cytochromu P-450 CYP2C19
- Ryfampicyna
- Warfaryna
- Flukonazol
Inne numery identyfikacyjne badania
- 0807M38361
- P01GM032165-26 (Grant/umowa NIH USA)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Control - Warfarin only
-
Mỹ Đức HospitalZakończony
-
Johnson & Johnson Vision Care, Inc.ZakończonyOstrość widzeniaStany Zjednoczone
-
Evidence-Based Practice Institute, Seattle, WANational Institute of Mental Health (NIMH); University of MarylandJeszcze nie rekrutacjaZaburzenia zachowania dzieci | Samobójstwo i samookaleczenieStany Zjednoczone
-
Rethink Medical SLRekrutacyjnyJakość życia | Powikłania związane z cewnikiem | Zakażenie dróg moczowych związane z cewnikiemHiszpania
-
Rethink Medical SLWycofaneZatrzymanie moczu | Powikłania związane z cewnikiem | Zakażenie dróg moczowych związane z cewnikiemHiszpania
-
Johns Hopkins UniversityZakończony
-
Indiana UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...RekrutacyjnyZapobieganie ciąży | Wykorzystanie opieki zdrowotnej | Stosowanie środków antykoncepcyjnychStany Zjednoczone
-
Massachusetts General HospitalEuropean CommissionZakończonyUogólnione zaburzenie lękoweStany Zjednoczone
-
University of Southern CaliforniaPendulum TherapeuticsWycofaneCukrzyca typu 2 | Objawy żołądkowo-jelitoweStany Zjednoczone
-
Icahn School of Medicine at Mount SinaiRekrutacyjny